XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy

Journal of Thoracic Oncology

Volumn 4, Issue 6, 2009, Pages 736-740

  Gatzemeier, Ulrich ^a   Ciuleanu, Tudor ^b   Dediu, Mircea ^c   Ganea Motan, Elena ^d   Lubenau, Heinz ^e   Del Giglio, Auro ^f,g  

^a Centre of Pneumology and Thoracic Surgery   (Germany)

^b THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^c Institutul Oncologic Al Trestioreanu   (Romania)

^d Spitalul Judetean de Urgenta   (Romania)

^e BioGeneriX AG   (Germany)

^f FACULDADE DE MEDICINA DO ABC   (Brazil)

^g HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Chemotherapy; G CSF; Lung cancer; Neutropenia; XM02

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG; XM 02; ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACKACHE; BODY TEMPERATURE; BONE PAIN; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE DURATION; DISEASE SEVERITY; DISORIENTATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; ECZEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL DISEASE; HUMAN; HYPONATREMIA; INCIDENCE; INJECTION SITE PAIN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THORAX PAIN; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT DURATION; TREATMENT WITHDRAWAL; VOMITING; WEAKNESS; CHEMICALLY INDUCED DISORDER; LUNG TUMOR; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHARMACOKINETICS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEMALE; FILGRASTIM; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SMALL CELL LUNG CARCINOMA; SURVIVAL RATE; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 67849119891     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181a52964     Document Type: Article

References (9)

1. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20:727-731. (Pubitemid 34111380)
2. Dale DC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs 2002;62(Suppl 1):1-15.
3. Martin-Christin F. Granulocyte colony stimulating factors: how different are they? How to make a decision? Anticancer Drugs 2001;12:185-191. (Pubitemid 32269913)
4. Amgen Ltd. Summary of Product Characteristics: Neupogen 30 MU and 48 MU Solution for Injection. Electronic Medicines Compendium, 2009. Available at: http://emc.medicines.org.uk/medicine/7907/SPC/ Neupogen+30MU+and+48MU+solution+for+injection/. Accessed February 20, 2009.
5. Spira A, Ettinger DS. In Wood A (Ed.). Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392. (Pubitemid 38101633)
6. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
7. Timmer-Bonte JN, de Boo TM, Smit HJ, et al. Prevention of chemotherapy- induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized Phase III study. J Clin Oncol 2005;23:7974-7984.
8. del Giglio A, Eniu A, Ganea-Motan D, Topuzov E, Lubenau H. XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy. BMC Cancer 2008;8:332.
9. Engert A, Griskevicius L, Zyuzgin Y, Lubenau H, del Giglio A. XM02, the first G-CSF biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin-lymphoma receiving chemotherapy. Leuk Lymphoma. In press.